Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a report issued on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Evogene Price Performance

Shares of NASDAQ:EVGN opened at $1.54 on Wednesday. The business’s 50-day moving average is $1.59 and its 200 day moving average is $2.67. Evogene has a 1 year low of $1.20 and a 1 year high of $10.40. The firm has a market capitalization of $8.26 million, a P/E ratio of -0.34 and a beta of 1.30.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings data on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%.

Institutional Investors Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC purchased a new position in Evogene Ltd. (NASDAQ:EVGN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.